Notably, combination therapy of the DC-targeted vaccine with anti-Tim-3 antibody treatment led to improved anti-tumor efficacy, thus supporting the β-catenin/Tim-3 axis in cDC1s as a new target for therapeutic intervention. This evidence concerns the gene HAVCR2 and neoplasm.